Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Biotech announces registration pathway and clinical development plan

April 12 (Reuters) - Oncolytics Biotech Inc  ONC.TO  - 
    * Announces registration pathway and clinical development 
plan 
    * Announced initial registration pathway and clinical 
development plan for reolysin, proprietary immuno-oncology viral 
agent 
    * Trial will recruit approximately 44 patients across up to 
six myeloma UK clinical trial network centres in UK 
    * Oncolytics and Celgene UK & Ireland are providing 
respective products for muk eleven 
    * Oncolytics is providing Reolysin and Celgene UK & Ireland 
is providing imnovid and revlimid 
 
Source text for Eikon:  ID:nPn8k2QFsa  
Further company coverage:  ONC.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com))

Recent news on Oncolytics Biotech

See all news